Goldman Sachs analyst Paul Choi maintained a Sell rating on FibroGen (FGEN – Research Report) today. The company’s shares opened today at $18.60.
Choi covers the Healthcare sector, focusing on stocks such as FibroGen, PTC Therapeutics, and Ascendis Pharma. According to TipRanks, Choi has an average return of 7.3% and a 52.55% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for FibroGen with a $28.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $25.69 and a one-year low of $8.67. Currently, FibroGen has an average volume of 891.9K.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More on FGEN:
- FGEN Slides after DMD Candidate Fails In Phase 3 Trial
- FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
- FibroGen to Present at Jefferies Global Healthcare Conference
- FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
- FibroGen Reports First Quarter 2023 Financial Results
